Procit faces safety questions; DEA rule on eRx for controlled drugs challenged;

> Johnson & Johnson's Procrit anemia drug is facing FDA scrutiny now that research data has emerged suggesting patients taking it were more likely to die than with a placebo. FiercePharma

> A New York-based group has issued a set of recommendations this week that take on what may be one of the biggest problems RHIOs face--setting uniform standards for getting consent for patient data sharing. FierceHealthIT

> U.K. men afraid to discuss a small, very embarrassing problem with their doctors will now be able to get their prescription online. FiercePharma

> One of the nation's largest and most influential health IT groups is slamming Rep. Pete Stark's bill intended to help subsidize and promote the use of health IT. FierceHealthIT

And Finally... Hey, give the guy a break--his job is very stressful. Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.